Clinical trials: Stage IV Small Cell Lung Cancer
Anxiety Disorder, Recurrent Non-small Cell Lung Cancer
Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers
This pilot clinical trial studies cognitive behavioral therapy in treating anxiety in patients with stage IV non-small cell lung cancer and their caregivers.
- Conditions
- Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01729689
- Testing
- counseling intervention, questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Lung Cancer
Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003762
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 106 people
- Sponsor
- Alliance for Clinical Trials in Oncology
NSCLC Stage IV, EGFR Gene Mutation
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.
- Trial name
- TROP-LUNG (NCT07548060)
- Testing
- sacituzumab tirumotecan
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Phase II Avastin Trial for Stage IIIB/IV NSCLC
This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).
- Trial name
- NCT00766246
- Testing
- bevacizumab, docetaxel, carboplatin
- Volunteers
- 125 people
- Sponsor
- Pharmatech
Lung Cancer, Non-Small Cell
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and safety of GSK1120212 compared with docetaxel in the second line setting for subjects with locally advanced or metastatic (Stage IV)…
- Trial name
- NCT01362296
- Testing
- GSK1120212, docetaxel
- Where
- 60 sites in United States, France and 6 more
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054210
- Testing
- carboplatin, paclitaxel, paclitaxel poliglumex
- Where
- 35 sites in United States, Canada
- Sponsor
- CTI BioPharma
Lung Cancer, NSCLC
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
- Conditions
- Lung Cancer, NSCLC, NSCLC Stage IV
- Trial name
- TUMORIN (NCT05332925)
- Testing
- Standard of care immune checkpoint inhbitors
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jun Zhang, MD, PhD
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer, NSCLC
FGFR Inhibitor in FGFR Dysregulated Cancer
In the FIND trial, Non Small Cell Lung Carcinoma (NSCLC) patients with Fibroblast Growth Factor Receptor (FGFR) genetic alteration will be treated with the selective FGFR1-4 inhibitor erdafitinib.
- Conditions
- Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer
- Trial name
- FIND (NCT03827850)
- Testing
- ERDAFITINIB
- Where
- 11 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Lung Cancer Group Cologne
Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ
Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab
This phase II trial is studying the side effects and how well giving radiation therapy together with bevacizumab, paclitaxel, and carboplatin works in treating patients with unresectable stage IIIB or stage IV non-small cell lung…
- Conditions
- Adenosquamous Cell Lung Cancer, Drug/Agent Toxicity by Tissue/Organ, Hemoptysis, Squamous Cell Lung Cancer
- Trial name
- NCT00387374
- Testing
- bevacizumab, paclitaxel, carboplatin
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00469976
- Testing
- bevacizumab, carboplatin, enzastaurin hydrochloride
- Sponsor
- Eastern Cooperative Oncology Group
Non Small Cell Lung Carcinoma
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by…
- Trial name
- SELINE (NCT00608868)
- Testing
- Gefitinib
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Stage IV Non-small Cell Lung Cancer
Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer
The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).
- Trial name
- NCT02470468
- Testing
- DCVAC add on to SOC, DCVAC and immune enhancers add on to SOC, Standard of Care Chemotherapy
- Where
- 18 sites in Czechia, Slovakia
- Volunteers
- 105 people
- Sponsor
- SOTIO a.s.
Bladder Cancer, Breast Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors
RATIONALE: The LMB-9 immunotoxin may be able to locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced solid tumors.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00019435
- Testing
- LMB-9 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
This is an open-label, single-arm, phase II, multicenter study designed to evaluated the efficacy and safety of atezolizumab in combination with bevacizumab in PD-L1-selected patients with Stage IIIB-IV Non-Squamous NSCLC…
- Trial name
- NCT04426825
- Testing
- Atezolizumab, Bevacizumab
- Where
- 10 sites in China
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
This 4 arm study will assess the optimal starting dose of Mircera in the treatment of anemia in patients with non-small cell lung cancer receiving first line myelosuppressive chemotherapy.
- Trial name
- NCT00327535
- Testing
- Darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 68 sites in Australia, Austria and 13 more
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
This phase I trial studies the safety, side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back after a…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT02496663
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 15 sites in United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897533
- Testing
- gene mapping, polymorphism analysis, diagnostic laboratory biomarker analysis
- Volunteers
- 137 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT03191149
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test
- Where
- 347 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)